These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 32639233)
41. Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. Chai PR; Ferro EG; Kirshenbaum JM; Hayes BD; Culbreth SE; Boyer EW; Erickson TB J Med Toxicol; 2020 Jul; 16(3):314-320. PubMed ID: 32514696 [TBL] [Abstract][Full Text] [Related]
42. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363 [TBL] [Abstract][Full Text] [Related]
43. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. Borba MGS; Val FFA; Sampaio VS; Alexandre MAA; Melo GC; Brito M; Mourão MPG; Brito-Sousa JD; Baía-da-Silva D; Guerra MVF; Hajjar LA; Pinto RC; Balieiro AAS; Pacheco AGF; Santos JDO; Naveca FG; Xavier MS; Siqueira AM; Schwarzbold A; Croda J; Nogueira ML; Romero GAS; Bassat Q; Fontes CJ; Albuquerque BC; Daniel-Ribeiro CT; Monteiro WM; Lacerda MVG; JAMA Netw Open; 2020 Apr; 3(4):e208857. PubMed ID: 32330277 [TBL] [Abstract][Full Text] [Related]
44. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535 [TBL] [Abstract][Full Text] [Related]
45. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern? Kamp TJ; Hamdan MH; January CT J Am Heart Assoc; 2020 Jun; 9(12):e016887. PubMed ID: 32463308 [No Abstract] [Full Text] [Related]
46. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial. Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597 [TBL] [Abstract][Full Text] [Related]
47. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe? Schluenz LA; Ramos-Otero GP; Nawarskas JJ Cardiol Rev; 2020; 28(5):266-271. PubMed ID: 32769401 [TBL] [Abstract][Full Text] [Related]
48. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings. Mvumbi DM Med Hypotheses; 2020 Oct; 143():109912. PubMed ID: 32498009 [No Abstract] [Full Text] [Related]
49. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Patil VM; Singhal S; Masand N Life Sci; 2020 Aug; 254():117775. PubMed ID: 32418894 [TBL] [Abstract][Full Text] [Related]
50. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D; Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924 [TBL] [Abstract][Full Text] [Related]
51. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Zou L; Dai L; Zhang X; Zhang Z; Zhang Z Arch Pharm Res; 2020 Aug; 43(8):765-772. PubMed ID: 32740801 [TBL] [Abstract][Full Text] [Related]
52. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. Oren O; Yang EH; Gluckman TJ; Michos ED; Blumenthal RS; Gersh BJ Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008688. PubMed ID: 32436730 [No Abstract] [Full Text] [Related]
53. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern? Marmor MF Am J Ophthalmol; 2020 May; 213():A3-A4. PubMed ID: 32247518 [No Abstract] [Full Text] [Related]
54. Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial. Calderón JM; Zerón HM; Padmanabhan S Trials; 2020 Jun; 21(1):504. PubMed ID: 32513231 [TBL] [Abstract][Full Text] [Related]
55. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Axfors C; Schmitt AM; Janiaud P; Van't Hooft J; Abd-Elsalam S; Abdo EF; Abella BS; Akram J; Amaravadi RK; Angus DC; Arabi YM; Azhar S; Baden LR; Baker AW; Belkhir L; Benfield T; Berrevoets MAH; Chen CP; Chen TC; Cheng SH; Cheng CY; Chung WS; Cohen YZ; Cowan LN; Dalgard O; de Almeida E Val FF; de Lacerda MVG; de Melo GC; Derde L; Dubee V; Elfakir A; Gordon AC; Hernandez-Cardenas CM; Hills T; Hoepelman AIM; Huang YW; Igau B; Jin R; Jurado-Camacho F; Khan KS; Kremsner PG; Kreuels B; Kuo CY; Le T; Lin YC; Lin WP; Lin TH; Lyngbakken MN; McArthur C; McVerry BJ; Meza-Meneses P; Monteiro WM; Morpeth SC; Mourad A; Mulligan MJ; Murthy S; Naggie S; Narayanasamy S; Nichol A; Novack LA; O'Brien SM; Okeke NL; Perez L; Perez-Padilla R; Perrin L; Remigio-Luna A; Rivera-Martinez NE; Rockhold FW; Rodriguez-Llamazares S; Rolfe R; Rosa R; Røsjø H; Sampaio VS; Seto TB; Shahzad M; Soliman S; Stout JE; Thirion-Romero I; Troxel AB; Tseng TY; Turner NA; Ulrich RJ; Walsh SR; Webb SA; Weehuizen JM; Velinova M; Wong HL; Wrenn R; Zampieri FG; Zhong W; Moher D; Goodman SN; Ioannidis JPA; Hemkens LG Nat Commun; 2021 Apr; 12(1):2349. PubMed ID: 33859192 [TBL] [Abstract][Full Text] [Related]
56. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given. Malviya A Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688 [No Abstract] [Full Text] [Related]
57. Chloroquine and hydroxychloroquine during pregnancy: What do we know? Lacroix I; Bénévent J; Damase-Michel C Therapie; 2020; 75(4):384-385. PubMed ID: 32418732 [No Abstract] [Full Text] [Related]
58. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926 [TBL] [Abstract][Full Text] [Related]
59. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. Piszczatoski CR; Powell J Ann Pharmacother; 2020 Aug; 54(8):827-831. PubMed ID: 32389025 [TBL] [Abstract][Full Text] [Related]
60. Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis. Das RR; Behera B; Mishra B; Naik SS Indian J Med Microbiol; 2020; 38(3 & 4):265-272. PubMed ID: 33154234 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]